Life-Saving Potential that is Too Precious to Waste
Cord blood is rich in hematopoietic (blood-forming) stem cells
It contains valuable, therapeutic stem cells
- Unrestricted somatic stem cells (USSC)
The discovery of unrestricted somatic stem cells (USSC), a non-hematopoietic stem cell population, brought cord blood (CB) to the forefront of regenerative medicine, a new field that uses cord blood to repair damaged tissues and organs (Matsumoto T and Mugishima H, Int J Stem Cells, 83-89 Nov 2(2) 2009).
- Mesenchymal stem cells (MSC)
Mesenchymal stem cells are multipotent stem cells that can differentiate into a variety of cell types, such as osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells) and more. (A.Malgieri, E. Kantzari, M. Patrizi and S. Gambaradella, IJCEM, 248-269, 2010)
- Endothelial progenitor cells (EPC)
The use of human cord-blood-derived EPCs is used for induction of angiogenesis in critically ischemic diseases.
It has been successfully used to treat many types of life-threatening diseases
Stem cells have been used to treat many types of malignant and non-malignant life-threatening diseases. Cord blood stem cells have saved the lives of over forty thousand patients worldwide.
It has been recommended that transplanting cord blood stem cells with a perfect HLA match should be the first choice over bone marrow to treat malignant diseases (Smith A. and Wagner J. BJH147, 246–261, 2009).
100% Match with Your Baby (Autologous Use)
The number of the autologous therapy cases (treatment with the baby’s own cord blood stem cells) has raised exponentially, compared with the growth in the number of treatment with cord blood stem cells donated by others being performed since 2006. (Verter F and Nietfeld J. Cytotherapy Vol.12 Supplement 1, 2010 (abstract)).
Since there is a chance that a child will match a sibling perfectly, it is more beneficial to save cord blood stem cells from each child to increase the probability of matching a family member who may develop a disease requiring stem cell therapy. Moreover, the additional cord blood units can be used for patients whose treatments require two cord blood units.
Autologous transplantation of cord blood could become an important therapy
It is increasing much faster than allogeneic transplantation
The rising rate of autologous therapy (treatment with the donor’s own cord blood stem cells) exceeds exponential growth, compared with linear growth in the number of allogeneic cord blood transplants being performed (NMDP) (treatment with cord blood stem cells donated by others) (Verter F and Nietfeld J. Cytotherapy Vol.12 Supplement 1, 2010 (abstract)).
Cord blood can only be collected at birth but the life saving potential of these valuable cells can last a life-time.